<DOC>
	<DOCNO>NCT02086604</DOCNO>
	<brief_summary>This Phase I clinical trial study side effect maximum tolerate dose ( MTD ) combination brentuximab vedotin ( BV ) lenalidomide treatment patient relapse refractory diffuse large B-cell lymphoma ( DLBCL ) .</brief_summary>
	<brief_title>Brentuximab Vedotin Lenalidomide Relapsed Refractory Diffuse Large B-cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Relapsed refractory de novo transform DLBCL disease follow least one prior systemic therapy ( DLBCL ) . CD30 immunohistochemical stain use antiCD30 BerH2 antibody must available recent biopsy specimen . During dose escalation , patient either CD30 positive CD30 negative . During dose expansion , 15 patient must CD30 positive 15 patient must CD30 negative . PostASCT candidate ASCT . Prior allogeneic stem cell transplant allow patient immunosuppressive evidence active GVHD . Prior treatment brentuximab vedotin allow provided patient progress BV within 30 day last dose BV . Patients must least 3 month last dose BV . Bidimensional measurable disease least 1.5 cm great transverse diameter document CT PET/CT . At least 18 year age . ECOG performance status ≤ 2 Bone marrow organ function define : Absolute neutrophil count ( ANC ) ≥ 1,000/mcl Platelets ≥ 50,000/mcl Serum bilirubin ≤ 1.5 x institutional upper limit normal ( IULN ) OR serum bilirubin ≤ 3.0 x IULN patient Gilbert 's disease document hepatic involvement NHL Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 2.5 x IULN OR ALT AST ≤ 5.0 x IULN patient document hepatic involvement NHL Creatinine clearance ≥ 60 mL/min/1.73 m2 calculate CockcroftGault Women childbearing potential must follow pregnancy test requirement outline Revlimid REMS® program material . This define either commit continue abstinence heterosexual intercourse begin TWO acceptable method contraception ( one highly effective method one additional effective method AT THE SAME TIME ) least 28 day prior start lenalidomide , duration study participation , 28 day follow last dos brentuximab vedotin lenalidomide . Women childbearing potential must also agree ongoing pregnancy test . Men must agree use latex condom sexual contact woman childbearing potential even successful vasectomy . All patient must counsel minimum every 28 day pregnancy precaution risk fetal exposure . Should woman become pregnant suspect pregnant participating study , must inform treat physician immediately . All study participant must register mandatory Revlimid REMS® program willing comply requirement . Per standard Revlimid REMS® program requirement , physician prescribe lenalidomide research subject enrol trial , must register , must comply , requirement Revlimid REMS® program . Able understand willing sign IRB approve write informed consent document ( legally authorize representative , applicable ) . Primary mediastinal Bcell lymphoma A history primary invasive malignancy remission least 3 year current diagnosis myelodysplastic syndrome ( MDS ) immature leukemia acute myeloid leukemia ( AML ) . Known active cerebral/meningeal lymphoma . Present history progressive multifocal leukoencephalopathy ( PML ) . NYHA Class III IV congestive heart failure . Active CTCAE version 4.03 grade 3 high viral , bacterial , fungal infection . Known positive hepatitis B surface antigen expression hepatitis B core antibody . Known active hepatitis C infection ( positive polymerase chain reaction ) antiviral therapy hepatitis C within 6 month prior first dos brentuximab vedotin lenalidomide . Known positive HIV . Receiving chemotherapy , radiotherapy , biologics , and/or antitumor treatment immunotherapy complete least 3 week prior study entry , unless underlying disease progress therapy . Currently receive investigational agent . Known hypersensitivity excipient contain drug formulation brentuximab vedotin lenalidomide . Pregnant and/or breastfeeding . Women childbearing potential must negative serum urine pregnancy test sensitivity least 50 mIU/mL within 1014 day prior within 24 hour start lenalidomide . Receiving immunosuppressive therapy . Refractory prior therapy brentuximab vedotin ( evidence progression within 30 day last dose ) . Prior therapy lenalidomide .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>